Why Do Carbapenem Antibiotics Cause Higher Rates of Clostridium difficile & Superinfections?
JUN 05, 2017 | CONTAGION® EDITORIAL STAFF
Khalid Eljaaly, PharmD, MS, CAPPS, BCPS, Contagion Editorial Advisory Board member, postdoctoral research fellow on infectious diseases and antimicrobial stewardship, the University of Arizona, College of Pharmacy, explains why carbapenem antibiotics cause higher rates of C. diff and superinfections.
Interview Transcript (slightly modified for readability)
“We believe [that] it is because carbapenem has [more] broad-spectrum of activity than other antibiotics. This leads to inhibition of microflora and [the] overgrowth of opportunistic organisms.
We found that when we compared imipenem or meropenem versus other antibiotics, that it was associated with more superinfections and Clostridium difficile. We had around 8 randomized clinical trials that looked at superinfections, [and so] we were able to do a subgroup analysis comparing a carbapenem versus the typical comparator, which is an antipseudomonal beta-lactam, such as piperacillin/tazobactam or cefepime, and we found a higher [incidence] of superinfection with carbapenem, compared with an antipseudomonal beta-lactam.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512